Sign In to Follow Application
View All Documents & Correspondence

Method For Treating Muscular Dystrophy By Targeting Dmpk Gene

Abstract: Polynucleotides comprising the following base sequences: (a) a base sequence encoding a fusion protein of a nuclease-deficient CRISPR effector protein and a transcriptional repressor, and (b) a base sequence encoding a guide RNA targeting a continuous region of 18 to 24 nucleotides in length in a region set forth in SEQ ID NO: 127, SEQ ID NO: 46, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 88, SEQ ID NO: 91, SEQ ID NO: 133, SEQ ID NO: 137, SEQ ID NO: 117, or SEQ ID NO: 119 in an expression regulatory region of a human DMPK gene, are expected to be useful for treating muscular dystrophy.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
17 December 2021
Publication Number
04/2022
Publication Type
INA
Invention Field
BIOTECHNOLOGY
Status
Email
patent@depenning.com
Parent Application

Applicants

ASTELLAS PHARMA INC.
5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
MODALIS THERAPEUTICS CORPORATION
3-11-5, Nihonbashi-Honcho, Chuo-ku, Tokyo 1030023

Inventors

1. YOSHIMI, Eiji
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
2. OE, Tomoya
c/o Astellas Pharma Inc., 5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 1038411
3. YAMAGATA, Tetsuya
c/o Modalis Therapeutics Inc., 51 Moulton Street, Cambridge, Massachusetts 02138
4. CONNOLLY, Keith, M.
c/o Modalis Therapeutics Inc., 51 Moulton Street, Cambridge, Massachusetts 02138

Specification

Documents